Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines

International Journal of Oncology

Volumn 28, Issue 2, 2006, Pages 393-398

  Nakamura, Keiichiro ^a   Nasu, Yasutomo ^a   Hongo, Atsushi ^a   Matsuo, Tamaki ^a   Kodama, Junichi ^a   Ebara, Shin ^a   Nagai, Atsushi ^a   Abrzua, Fernando ^a   Kumon, Hiromi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Caspase; Hepsin; Ovarian cancer; p53 dependent apoptotic pathway

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CASPASE; HEPSIN; MESSENGER RNA; P53AIP1 PROTEIN, HUMAN; PROTEIN P53; SERINE PROTEINASE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG SCREENING; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TRANSFECTION; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39049181069     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.2.393     Document Type: Article

References (22)

1. Leytus SP, Loeb KR, Hagen FS, Kurachi K and Davie EW: A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 27: 1067-1074, 1988.
2. Tsuji A, Torres-Rosado A, Arai T, Le Beau MM, Lemons RS, Chou SH and Kurachi K: Hepsin, a cell membrane-associated protease. J Biol Chem 266: 16948-16953, 1991.
3. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, Parham GP and O'Brien TJ: Hepsin, a cell surface serine protease identified in hepatoma cells, is expressed in ovarian cancer. Cancer Res 57: 2884-2887, 1997.
4. Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM and Kisiel W: Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost 79: 876-877, 1998.
5. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001.
6. Ernst T, Hergenhahn M, Kenzelmann M, et al: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma. Am J Pathol 160: 2169-2180, 2002.
7. Wilhelm J, Hahn M and Pingoud A: Influence of DNA target melting behavior on real-time PCR quantification. Clin Chem 46: 1738-1743, 2000.
8. Srikantan V, Valladares M, Rhim JS, Moul JW and Srivastava S: Hepsin inhibits cell growth/invasion in prostate cancer cells. Cancer Res 62: 6812-6816, 2002.
9. Gottlieb TM and Oren M: p53 in growth control and neoplasia. Biochim Biophys Acta 1287: 77-102, 1996.
10. Rich T, Allen RL and Wyllie AH: Defying death after DNA damage. Nature 407: 777-783, 2000.
11. Nakano K and Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694, 2001.
12. Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673-682, 2001.
13. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T and Tanaka N: Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058, 2000.
14. Schuler M and Green DR: Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 29: 684-688, 2001.
15. Evans DL and Mansel RE: Molecular evolution and secondary structural conservation in the B-cell lymphoma leukemia 2 (bcl-2) family of proto-oncogene products. J Mol Evol 41: 775-783, 1995.
16. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR and Reed JC: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56: 2422-2427, 1996.
17. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y and Arakawa K: p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 62: 2883-2889, 2002.
18. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y and Arakawa H: p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 61: 8256-8262, 2001.
19. Kondo S, Barna BP, Morimura T, Takeuchi J, Yuan J, Akbasak A and Barnett GH: Interleukin-1 beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res 55: 6166-6171, 1995.
20. Henkels KM and Turchi JJ: Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 59: 3077-3083, 1999.
21. Wu GS and Ding Z: Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21: 1-8, 2002.
22. Troy CM, Stefanis L, Prochiantz A, Greene LA and Shelanski ML: The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc Natl Acad Sci USA 93: 5635-5640, 1996.